Advertisement

A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis

      Highlights

      • The largest ambispective study from a developing country on natalizumab and multiple sclerosis.
      • Natalizumab was found to be highly effective in Indian patients with MS.
      • Patients with RRMS and SPMS improved in relapse rate while EDSS improvement was observed only in the RRMS cohort.
      • The risk-benefit ratio appears highly favorable with no reports of PML.

      Abstract

      Background

      Natalizumab (NTZ) is increasingly being used in Indian multiple sclerosis (MS) patients. There are no reports on its safety and efficacy, especially with respect to the occurrence of progressive multifocal leukoencephalopathy (PML).

      Objectives

      To describe the patient characteristics, treatment outcomes, and adverse events, especially the occurrence of PML in NTZ-treated patients.

      Methods

      A multicentre ambispective study was conducted across 18 centres, from Jan 2012 to Dec 2021. Patients at and above the age of 18 years treated with NTZ were included. Descriptive and comparative statistics were applied to analyze data.

      Results

      During the study period of 9 years, 116 patients were treated with NTZ. Mean age of the cohort was 35.6 ± 9.7 years; 83/116 (71.6%) were females. Relapse rate for the entire cohort in the year before NTZ was 3.1 ± 1.51 while one year after was 0.20±0.57 (p = 0.001; CI 2.45 -3.35). EDSS of the entire cohort in the year before NTZ was 4.5 ± 1.94 and one year after was 3.8 ± 2.7 (p = 0.013; CI 0.16–1.36). At last follow up (38.3 ± 22.78 months) there were no cases of PML identified.

      Conclusions

      Natalizumab is highly effective and safe in Indian MS patients, with no cases of PML identified at last follow up.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alping P.
        • Frisell T.
        • Novakova L.
        Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
        Ann. Neurol. 2016; 79: 950-958
        • Brown J.W.L.
        • Coles A.
        • Horakova D.
        • Havrdova E.
        • Izquierdo G.
        • Prat A.
        • Girard M.
        • Duquette P.
        • Trojano M.
        • Lugaresi A.
        • Bergamaschi R.
        • Grammond P.
        • Alroughani R.
        • Hupperts R.
        • McCombe P.
        • Van Pesch V.
        • Sola P.
        • Ferraro D.
        • Grand'Maison F.
        • Terzi M.
        • Lechner-Scott J.
        • Flechter S.
        • Slee M.
        • Shaygannejad V.
        • Pucci E.
        • Granella F.
        • Jokubaitis V.
        • Willis M.
        • Rice C.
        • Scolding N.
        • Wilkins A.
        • Pearson O.R.
        • Ziemssen T.
        • Hutchinson M.
        • Harding K.
        • Jones J.
        • McGuigan C.
        • Butzkueven H.
        • Kalincik T.
        • Robertson N.
        • MSBase Study Group
        Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.
        JAMA. 2019; 321 (Erratum in: JAMA. 2020 Apr 7;323(13):1318. PMID: 30644981; PMCID: PMC6439772): 175-187https://doi.org/10.1001/jama.2018.20588
        • Butzkueven H.
        • Kappos L.
        • Wiendl H.
        • Trojano M.
        • Spelman T.
        • Chang I.
        • Kasliwal R.
        • Jaitly S.
        • Campbell N.
        • Ho P.R.
        • Licata S.
        Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
        J. Neurol. Neurosurg. Psychiatry. 2020; 91: 660-668
        • Clifford D.B.
        • De Luca A.
        • Simpson D.M.
        • Arendt G.
        • Giovannoni G.
        • Nath A.
        Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
        Lancet Neurol. 2010; 9: 438-446https://doi.org/10.1016/S1474-4422(10)70028-4
        • Derfuss T.
        • Kovarik J.M.
        • Kappos L.
        • Savelieva M.
        • Chhabra R.
        • Thakur A.
        • Zhang Y.
        • Wiendl H.
        • Tomic D.
        α4-integrin receptor desaturation and disease activity return after natalizumab cessation.
        Neurol. Neuroimmunol. Neuroinflamm. 2017; 4 (PMID: 28856176; PMCID: PMC5572051): e388https://doi.org/10.1212/NXI.0000000000000388
        • Foley J.F.
        • Nair K.V.
        • Vollmer T.
        • Stephenson J.J.
        • Niecko T.
        • Agarwal S.S.
        • Watson C.
        Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.
        Patient Prefer. Adherence. 2017; 11 (PMID: 28670113; PMCID: PMC5481282): 1035-1048https://doi.org/10.2147/PPA.S134865
        • Foley J.F.
        • Nair K.V.
        • Vollmer T.
        • Stephenson J.J.
        • Niecko T.
        • Agarwal S.S.
        • Watson C.
        Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.
        Patient Prefer Adherence. 2017; 11 (PMID: 28670113; PMCID: PMC5481282): 1035-1048https://doi.org/10.2147/PPA.S134865
        • GiovannoniG Kappos L
        • Berger J.
        Updated Incidence of Natalizumab Associated Progressive Multifocal Leukoencephalopathy (PML) and its relationship with natalizumab exposure overTime.
        in: Presented at: 2020 American Academy of Neurology (AAN) Annual Meeting, Toronto, Canada2020 (April 25th May 1st)
        • He A.
        • Merkel B.
        • Brown J.W.L.
        • Zhovits Ryerson L.
        • Kister I.
        • Malpas C.B.
        • Sharmin S.
        • Horakova D.
        • Kubala Havrdova E.
        • Spelman T.
        • Izquierdo G.
        • Eichau S.
        • Trojano M.
        • Lugaresi A.
        • Hupperts R.
        • Sola P.
        • Ferraro D.
        • Lycke J.
        • Grand'Maison F.
        • Prat A.
        • Girard M.
        • Duquette P.
        • Larochelle C.
        • Svenningsson A.
        • Petersen T.
        • Grammond P.
        • Granella F.
        • Van Pesch V.
        • Bergamaschi R.
        • McGuigan C.
        • Coles A.
        • Hillert J.
        • Piehl F.
        • Butzkueven H.
        • Kalincik T.
        MSBase study group. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
        Lancet Neurol. 2020; 19: 307-316
        • Ho P.R.
        • Koendgen H.
        • Campbell N.
        • Haddock B.
        • Richman S.
        • Chang I.
        Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
        Lancet Neurol. 2017; 16: 925-933https://doi.org/10.1016/S1474-4422(17)30282-X)
        • Lo Re M.
        • Capobianco M.
        • Ragonese P.
        Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers.
        Neurol. Ther. 2015; 4: 147-157
        • Mathew T.
        • John S.K.
        • Kamath V.
        • Murgod U.
        • Thomas K.
        • Baptist A.A.
        • Therambil M.
        • Shaji A.
        • Nadig R.
        • Badachi S.
        • Souza D.D.
        • Shivde S.
        • Avati A.
        • Sarma G.R.K.
        • Sharath Kumar G.G.
        • Deepalam S.
        • Parry G.J
        Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country.
        Mult. Scler. Relat. Disord. 2020; 43 (Epub 2020 May 24. PMID: 32485634)102210https://doi.org/10.1016/j.msard.2020.102210
        • Miller D.H.
        • Khan O.A.
        • Sheremata W.A.
        • et al.
        A controlled trial of natalizumab for relapsing multiple sclerosis.
        N. Engl. J. Med. 2003; 348: 15-23
        • Piehl F.
        • Mathew T.
        Low-dose rituximab should be used for treating MS in resource-limited settings: yes.
        Mult. Scler. 2022; (Epub ahead of print. PMID: 35437089)13524585221089890https://doi.org/10.1177/13524585221089890
        • Polman C.H.
        • O'Connor P.W.
        • Havrdova E.
        • Hutchinson M.
        • Kappos L.
        • Miller D.H.
        • Phillips J.T.
        • Lublin F.D.
        • Giovannoni G.
        • Wajgt A.
        • Toal M.
        • Lynn F.
        • Panzara M.A.
        • Sandrock A.W.
        AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
        N. Engl. J. Med. 2006; 354: 899-910
        • Prosperini L.
        • Kinkel R.P.
        • Miravalle A.A.
        • Iaffaldano Pietro
        • Fantaccini S
        Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.
        Ther. Adv. Neurol. Dis. 2019; 121756286419837809https://doi.org/10.1177/1756286419837809
        • Sangalli F.
        • Moiola L.
        • Ferrè L.
        • Radaelli M.
        • Barcella V.
        • Rodegher M.
        • Colombo B.
        • Martinelli Boneschi F.
        • Martinelli V.
        • Comi G
        Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients.
        Mult. Scler. Relat. Disord. 2014; 3 (DeLuca, Andrea [corrected to De Luca, Andrea]. PMID: 20298967.) (Epub 2014 Apr 13. PMID: 25877065)): 520-526https://doi.org/10.1016/j.msard.2014.04.003
        • Sangalli F.
        • Moiola L.
        • Ferrè L.
        • Radaelli M.
        • Barcella V.
        • Rodegher M.
        • Colombo B.
        • Martinelli Boneschi F.
        • Martinelli V.
        • Comi G
        Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients.
        Mult. Scler. Relat. Disord. 2014; 3 (Epub 2014 Apr 13. PMID: 25877065): 520-526https://doi.org/10.1016/j.msard.2014.04.003